Skip to main content
. 2016 Dec 8;13(2):770–776. doi: 10.3892/ol.2016.5476

Figure 1.

Figure 1.

IL-17 and IL-17R expression in HCC patients. (A) Serum samples from 30 HCC patients prior to and following Oxa treatment, as well as 30 samples from healthy controls, were assayed using an IL-17 ELISA. (B) Tissues samples from 30 HCC patients prior to and following Oxa treatment, as well as 30 samples from controls, were assayed by reverse transcription-quantitative polymerase chain reaction. *P<0.05 vs. Oxa-untreated group. IL-17, interleukin-17; IL-17R, IL-17 receptor; HCC, hepatocellular carcinoma; Oxa, oxaliplatin.